SBA
JAZZ icon

Seven Bridges Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Seven Bridges Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,221
Closed -$164K – 45
2017
Q4 		$164K Hold
1,221
– – 0.13% 101
2017
Q3 		$179K Buy
+1,221
New +$185K 0.15% 110

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Seven Bridges Advisors's JAZZ Position: Q1 2018 in Review

Seven Bridges Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2018, closing a stake of 1,221 shares — an estimated $164K sold.

Seven Bridges Advisors first reported a position in JAZZ in Q3 2017 and held it in 2 quarters. The position peaked at $179K in Q3 2017. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

  • Seven Bridges Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Seven Bridges Advisors sold 1,221 Jazz Pharmaceuticals shares in Q1 2018, an estimated $164K.
  • Seven Bridges Advisors first reported a position in Jazz Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Seven Bridges Advisors's Jazz Pharmaceuticals position peaked at $179K in Q3 2017.
  • 323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Seven Bridges Advisors's 13F filing for Q1 2018, filed 9 May 2018.